<DOC>
	<DOC>NCT01500057</DOC>
	<brief_summary>This is a Phase 4, prospective, open-label, randomized study of Greenlight XPS Laser versus BiVAP Saline Vaporization of the prostate in men with symptomatic Benign Prostatic Hyperplasia (BPH). The study consists of a screening phase, treatment, followed by follow-up visits at 1 week, 4 weeks, 3 months, 6 months, and 12 months.</brief_summary>
	<brief_title>Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>male over the age of 18 years present with symptomatic/ obstructive symptoms secondary to PBH requiring surgical intervention subjects must read, understand and sign the Informed Consent AUA ≥ 15 Qmax &lt; 15mL/sec Stopped BPH medication. Alpha blockers 15 days 5αreductase 3 months Prostate volume ≥ 30g PVR &gt; 300ml Current urine retention Previous surgical or invasive treatments (TURP, TUMT, TUNA) PSA ≥ 4 (must have negative biopsy within last 12 months) Neurogenic bladder Obstruction due to urethral stricture Any disorder or condition of the subject that the investigator believes will counter indicate their inclusion in the study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>enlarged prostate</keyword>
</DOC>